M. Puglisi

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 422 citations

Surgical Oncology, Malignant Disease, Relapsed Malignant Mesothelioma +8

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Gianluca Masi, E. Vasile, Fotios Loupakis et al. · JNCI Journal of the National Cancer Institute · 2010 · 188 citations

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Bristi Basu, Emma Dean, M. Puglisi et al. · Clinical Cancer Research · 2015 · 126 citations

Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.

Hedy L. Kindler, Arnaud Scherpereel, Luana Calabrò et al. · Journal of Clinical Oncology · 2016 · 45 citations

Surgical Oncology, Cancer Management, Immunology +20

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

Víctor Moreno, Richard D. Baird, Kinjal Shah et al. · Journal of Clinical Oncology · 2011 · 39 citations

Gdc-0941 Plasma Concentrations, Advanced Solid Tumors, Tumor Biology +17